“Applied and Translational Genomics” — What is new?  by Kumar, Dhavendra
Applied & Translational Genomics 1 (2012) 1–2
Contents lists available at SciVerse ScienceDirect
Applied & Translational Genomics
j ourna l homepage: www.e lsev ie r .com/ locate /atg“Applied and Translational Genomics” — What is new?Table 1
A template for applied and translational genomics research.
Genomics and biotechnology applications
Genomic laboratory applications
Bioinformatics tools for genomic research
Managing genome sequencing data
New drug discovery and development
Cell based therapy including stem cell technology
Improved and enhanced food production including crops
Innovations in genomic technologies
Nanogenomics
Genome vaccines
Bioenergy production
Genetics and genomics in clinical medicine
Diagnostic
Prognostication
Personalized therapeutics
Pharmacotherapy
Non-pharmacotherapy
Public and population health genomics
Genome database of high risk population groups for common medical diseases,
for example diabetes mellitus
Strategic planning for preventing major Mendelian diseases, for example sickle
cell disease, beta thalassemia, cystic ﬁbrosis, familial hypercholesterolemia, etc.
Microbial/pathogen genome databases, for example HIV, SARS, H1N1, etc.
Genomic surveillance for Regional and International infection control, for
example pandemic inﬂuenza
Bio-economic applications and developments
Biotechnology infrastructure for national and regional developments
Creation of jobs and revenue from teaching and training opportunities
Biofuel industrial applications from plants, algae and grasses
Fortiﬁed and bulk crop production, for example maize and rice
Selective and improved plant food production
Improved livestock for human consumption
Marine genomics and ﬁshery industry
Development of supporting ﬁnancial institutions and networks
Banking, venture capital, investments, share capital, etc.
(continued on next page)Among the many high expectations and promises witnessed at the
dawn of the new millennium were the completion of the human
genome project (HGP) and the commencement of the genomics era.
However, the genomic era had begun well before the landmark and
highly ambitious project to sequence the entire human genome was
even conceived. There are several examples of major pre-genome
era achievements. These include the successful employment of new
DNA analytical methods in the mapping of some of the critical
genes and the deciphering of adjoining genomic regions related to
non-curable human diseases. DNA recombinant technology led to
the discovery and development of several protein products
revolutionizing the treatment and prevention of some incurable
human diseases. And the application of genetic analysis methods
helped in sequencing microbial genomes. All of these achievements
were possible from systematic and targeted collective research efforts
in applied and translational genetics and biotechnology.
In the genomic context, the foundation for applied and translational
genomics was thus laid well before the seminal completion of the HGP.
Since the completion of HGP, the rapid accumulation of enormous data
and information has crossed all boundaries beyond any imagination.
Today a young graduate of cell and molecular biology and genetics
enjoys describing some of the most complicated laboratory methods
that were virtually impossible to comprehend even by some senior
geneticists and molecular biologists who later accepted the challenge
to sequence human and other genomes. A number of laboratory
methods supported by sophisticated information technology hardware
and advanced bioinformatics tools are now in routine use across many
nations on all continents. While some leading centers continue to
invest time and resources in basic genomic and molecular biology
research, a large number of research establishments are engaged in
developing new techniques applicable in wide ranging areas including
biotechnology, pharmaceutical manufacturing, medicine and health,
agriculture and horticulture, marine and ﬁshery, animal welfare and
veterinary science, and climate friendly efﬁcient bio-energy produc-
tion. Each speciﬁc ﬁeld and specialist area would further require pains-
taking and intensive research efforts and investment to translate the
selected application into practical, safe and efﬁcient use. It is often
not possible to delimit boundaries between applied and translational
research, as both are intricately linked and move forward together to
achieve the desired goal.
This introductory editorial note outlines the available evidence and
identiﬁes potential areas in which applied and translational genomics
research might produce effective and efﬁcient measurable outcomes.
Like any other scientiﬁc and technological ﬁeld, an important outcomes
measure should be the meeting of societal expectations in wide rang-
ing domains including economic gains, improving living standards,
compatibility with socio-cultural and religious practices, and alignment2212-0661 © 2012 Elsevier B.V.
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Open access under CC BY-NC-ND license. with the contemporary ethical, moral and legal requirements. There
are several potential areas where rapid advances in scientiﬁc under-
standing and avenues for translational research would need to be
seriously considered. Naturally any such listing would not be sufﬁcient
and might not be truly representative of all aspects of applied and
translational genomics research. Nevertheless, it might be beneﬁcial
to leading research establishment and young investigators to be
aware of some of the leading areas (Table 1).
For most researchers and established professionals, reporting and
publishing peer review reports and sharing data might not be too
onerous. There are several journals and on-line publishing channels
with a genomic preﬁx or sufﬁx. The proposed new genomics journal by
Elsevier is expected to complement the genomics portfolio and aims to
Table 2
Scope and remit of ‘Applied and Translational Genomics’.
• Genome sequencing methods
• Genomic variation (copy number/SNPs)
• Comparative genomics
• Functional genomics/proteomics
• Applied bio-systems/systems biology
• Bioinformatics (new purpose built/designed soft ware/program)
• Bio banking (cell repository; DNA banking)
• Data banking/databases
• Applied biotechnology (laboratory development and support)
• Clinical cytogenomics/clinical genomics (molecular diagnostics)
• Genomic and personalized medicine (evidence-based medicine)
• Public/population health (screening and targeting selected population; large
scale infection control and preventive measures)
• Pharmaceutical industry (new drugs and vaccines)
• Nutrigenomics (speciﬁcally targeted design foods)
• Plant and agricultural genomics (enhanced/fortiﬁed crops and animal food
production)
• Ecogenomics (improved sanitation and environmental pollution control)
• Bioeconomy (biotechnology, bio energy, biomaterials, etc.)
• Education and media (professional and public education; bio-information
through on-line/medial resources)
• Ethical, legal and social issues in translational genomics
• Legal and regulatory including Intellectual property rights (patenting etc.)
Genomics and society
Safe and acceptable use of the population genomic databases
Monitoring population movements
Emigration and immigration management
Disaster management—earthquakes, tsunamis, terrorist attacks, etc.
Ethical issues
Concerns of bioethics community
Consent and conﬁdentiality
Ownership
Prevention of harm to peoples from biomaterial procurement
Inappropriate use of the manpower resources
Diversion to questionable technology development
Inequitable distribution of ﬁnancial gains from genomic applications
Regulation and legal issues
Appropriate use of current statutory powers
Need for new statutes
Mechanisms for research governance
Patenting — new ideas, new methods, etc.
Biomaterial procurement — monitoring and reimbursement
Marketing of technology and products back to people and the state
Role of international agencies (WHO, FAO, World Bank, OECD, etc.).
Table 1 (continued)
2focus on publishing leading and cutting edge applied and translational
genomics research. The journal shall endeavor to publish material relat-
ed to industrial, agricultural, environmental, medicine and health, and
social and ethical applications of genome science and technologies
(Table 2).
A list of potential areas (Table 2) is appended to assist established and
new genomic investigators and professionals to consider publishing their
research, reviews and opinions in ‘Applied and Translational Genomics’.
The editorial policy shall be ethical and transparent by any international
standard. All material will be subjected to rigorous internal peer review
followed by external review wherever needed. The journal is open
access providing rights to authors who will contribute an agreed sum
for immediate on-line access. The executive staff for the journal shall
offer assistance to authors from less developed countries and those
with ﬁnancial constraints. The open access charge could be waived
completely in certain circumstances, for example invited review
articles. Members of the editorial board are fully aware that the scopeof the journal would need to be regularly revised as genome sciences
and technologies take humankind ahead in 21st century. It is anticipat-
ed that this new biomedical knowledge sharing and information
resourcewill meet its objectives and establish itself as a credible journal
in a rapidly advancing and highly competitive ﬁeld.
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